Regenera set to begin Singapore trials

By Melissa Trudinger
Tuesday, 03 August, 2004

Regenera (ASX: RGA) has received ethics committee approval to begin Phase III human clinical trials for its synthetic steroid drug Visagen at the Singapore Eye Research Institute.

The initial trial will test the treatment on cystoid macular oedema, and the company plans to expand the study with trials evaluating the therapy in age related macular degeneration, uveitis, diabetic macular oedema and as a co-treatment with photodynamic therapy.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

From raw to rare sugar: low-cal sweetener under development

Upcycling cauliflower waste into protein ingredients for future food

Keeping pace with changing appetites

Maize miller reaps the benefit of gravity metal detectors

The potential of AI technologies across the food supply chain

BESS project provides long-duration battery for NSW

Lessons in long-distance telemetry

GECA and ACOR launch national standard for recycling

Antibiotics in wastewater may contribute to antimicrobial resistance

Top super funds lacking investment in renewable energy

Customer demand exceeding capacity for Alpha HPA

Curtin University project to research sustainable gallium processing

How to extend the life of your motor bearings

Mars Petcare Wodonga expansion boosts manufacturing output

From Dark Age to Imperial: what Age of Empires teaches us about instrumentation